Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview
Irinotecan has been used in the treatment of various malignancies for many years. Still, the knowledge regarding this drug is expanding. The pharmacogenetics of the drug is the crucial component of response to irinotecan. Furthermore, new formulations of the drug are introduced in order to better de...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-07-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/14/4919 |
| _version_ | 1797562622511415296 |
|---|---|
| author | Mateusz Kciuk Beata Marciniak Renata Kontek |
| author_facet | Mateusz Kciuk Beata Marciniak Renata Kontek |
| author_sort | Mateusz Kciuk |
| collection | DOAJ |
| description | Irinotecan has been used in the treatment of various malignancies for many years. Still, the knowledge regarding this drug is expanding. The pharmacogenetics of the drug is the crucial component of response to irinotecan. Furthermore, new formulations of the drug are introduced in order to better deliver the drug and avoid potentially life-threatening side effects. Here, we give a comprehensive overview on irinotecan’s molecular mode of action, metabolism, pharmacogenetics, and toxicity. Moreover, this article features clinically used combinations of the drug with other anticancer agents and introduces novel formulations of drugs (e.g., liposomal formulations, dendrimers, and nanoparticles). It also outlines crucial mechanisms of tumor cells’ resistance to the active metabolite, ethyl-10-hydroxy-camptothecin (SN-38). We are sure that the article will constitute an important source of information for both new researchers in the field of irinotecan chemotherapy and professionals or clinicians who are interested in the topic. |
| first_indexed | 2024-03-10T18:31:33Z |
| format | Article |
| id | doaj.art-6eeac18bc0594b28a49af68d775cdc45 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T18:31:33Z |
| publishDate | 2020-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-6eeac18bc0594b28a49af68d775cdc452023-11-20T06:34:05ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-07-012114491910.3390/ijms21144919Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive OverviewMateusz Kciuk0Beata Marciniak1Renata Kontek2Doctoral School of Exact and Natural Sciences, University of Lodz, 90-237 Lodz, PolandDepartment of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Lodz, 90-237 Lodz, PolandDepartment of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Lodz, 90-237 Lodz, PolandIrinotecan has been used in the treatment of various malignancies for many years. Still, the knowledge regarding this drug is expanding. The pharmacogenetics of the drug is the crucial component of response to irinotecan. Furthermore, new formulations of the drug are introduced in order to better deliver the drug and avoid potentially life-threatening side effects. Here, we give a comprehensive overview on irinotecan’s molecular mode of action, metabolism, pharmacogenetics, and toxicity. Moreover, this article features clinically used combinations of the drug with other anticancer agents and introduces novel formulations of drugs (e.g., liposomal formulations, dendrimers, and nanoparticles). It also outlines crucial mechanisms of tumor cells’ resistance to the active metabolite, ethyl-10-hydroxy-camptothecin (SN-38). We are sure that the article will constitute an important source of information for both new researchers in the field of irinotecan chemotherapy and professionals or clinicians who are interested in the topic.https://www.mdpi.com/1422-0067/21/14/4919irinotecanSN-38topoisomerasesdrug combinationsnew formulationsdrug resistance |
| spellingShingle | Mateusz Kciuk Beata Marciniak Renata Kontek Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview International Journal of Molecular Sciences irinotecan SN-38 topoisomerases drug combinations new formulations drug resistance |
| title | Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview |
| title_full | Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview |
| title_fullStr | Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview |
| title_full_unstemmed | Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview |
| title_short | Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview |
| title_sort | irinotecan still an important player in cancer chemotherapy a comprehensive overview |
| topic | irinotecan SN-38 topoisomerases drug combinations new formulations drug resistance |
| url | https://www.mdpi.com/1422-0067/21/14/4919 |
| work_keys_str_mv | AT mateuszkciuk irinotecanstillanimportantplayerincancerchemotherapyacomprehensiveoverview AT beatamarciniak irinotecanstillanimportantplayerincancerchemotherapyacomprehensiveoverview AT renatakontek irinotecanstillanimportantplayerincancerchemotherapyacomprehensiveoverview |